E-viri
Recenzirano
Odprti dostop
-
Valanparambil, Rajesh M; Carlisle, Jennifer; Linderman, Susanne L; Akthar, Akil; Millett, Ralph Linwood; Lai, Lilin; Chang, Andres; McCook-Veal, Ashley A; Switchenko, Jeffrey; Nasti, Tahseen H; Saini, Manpreet; Wieland, Andreas; Manning, Kelly E; Ellis, Madison; Moore, Kathryn M; Foster, Stephanie L; Floyd, Katharine; Davis-Gardner, Meredith E; Edara, Venkata-Viswanadh; Patel, Mit; Steur, Conor; Nooka, Ajay K; Green, Felicia; Johns, Margaret A; O'Brein, Fiona; Shanmugasundaram, Uma; Zarnitsyna, Veronika I; Ahmed, Hasan; Nyhoff, Lindsay E; Mantus, Grace; Garett, Michael; Edupuganti, Srilatha; Behra, Madhusmita; Antia, Rustom; Wrammert, Jens; Suthar, Mehul S; Dhodapkar, Madhav V; Ramalingam, Suresh; Ahmed, Rafi
Journal of clinical oncology, 11/2022, Letnik: 40, Številka: 33Journal Article
To examine COVID-19 mRNA vaccine-induced binding and neutralizing antibody responses in patients with non-small-cell lung cancer (NSCLC) to SARS-CoV-2 614D (wild type WT) strain and variants of concern after the primary 2-dose and booster vaccination. Eighty-two patients with NSCLC and 53 healthy volunteers who received SARS-CoV-2 mRNA vaccines were included in the study. Blood was collected longitudinally, and SARS-CoV-2-specific binding and neutralizing antibody responses were evaluated by Meso Scale Discovery assay and live virus Focus Reduction Neutralization Assay, respectively. A majority of patients with NSCLC generated binding and neutralizing antibody titers comparable with the healthy vaccinees after mRNA vaccination, but a subset of patients with NSCLC (25%) made poor responses, resulting in overall lower (six- to seven-fold) titers compared with the healthy cohort ( = < .0001). Although patients age > 70 years had lower immunoglobulin G titers ( = < .01), patients receiving programmed death-1 monotherapy, chemotherapy, or a combination of both did not have a significant impact on the antibody response. Neutralizing antibody titers to the B.1.617.2 (Delta), B.1.351 (Beta), and in particular, B.1.1.529 (Omicron) variants were significantly lower ( = < .0001) compared with the 614D (WT) strain. Booster vaccination led to a significant increase ( = .0001) in the binding and neutralizing antibody titers to the WT and Omicron variant. However, 2-4 months after the booster, we observed a five- to seven-fold decrease in neutralizing titers to WT and Omicron viruses. A subset of patients with NSCLC responded poorly to the SARS-CoV-2 mRNA vaccination and had low neutralizing antibodies to the B.1.1.529 Omicron variant. Booster vaccination increased binding and neutralizing antibody titers to Omicron, but antibody titers declined after 3 months. These data highlight the concern for patients with cancer given the rapid spread of SARS-CoV-2 Omicron variant.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.